Preparing for the first at-home Leqembi Alzheimer’s dose starts with confirming that the treatment is appropriate, completing required MRI and risk assessments, receiving hands-on injection training, and creating a clear plan for side effects and emergencies. Leqembi IQLIK was FDA-approved on July 13, 2026, as an at-home starting regimen, but home administration is conditional: the first two consecutive doses must be given under direct healthcare-provider guidance before a patient or caregiver may be cleared to administer it independently. For example, a spouse who will give the injections should practice using both autoinjectors while the clinical team watches, corrects technique, and reviews which symptoms require immediate medical attention. The starting regimen is 500 milligrams injected subcutaneously once weekly, delivered through two 250-milligram autoinjectors. This differs from the earlier standard starting regimen of intravenous Leqembi at 10 milligrams per kilogram every two weeks.
Before the first dose, the treatment team should have confirmed beta-amyloid pathology, obtained a baseline brain MRI, reviewed APOE ε4 status and bleeding risks, and established dates for follow-up MRIs. FDA and the FDA-approved prescribing information provide the controlling safety and administration requirements. Leqembi is indicated for Alzheimer’s disease, but treatment should begin only in people with mild cognitive impairment or mild-dementia-stage disease—the population in which it was studied. It is not a labeled starting treatment for people without symptoms or for those with moderate or severe Alzheimer’s dementia. Families should expect continuing clinical supervision even when injections move into the home.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- How Should You Prepare for the First At-Home Leqembi Alzheimer’s Dose?
- Confirming Eligibility, Amyloid Pathology, and Baseline Safety
- APOE ε4, ARIA, and the Symptoms Families Must Recognize
- Building the Weekly Injection and MRI Schedule
- Injection Reactions, Hypersensitivity, and Bleeding Risks
- Preparing the Patient, Caregiver, and Home Environment
- What Happens After 18 Months of Leqembi Treatment?
- Frequently Asked Questions
How Should You Prepare for the First At-Home Leqembi Alzheimer’s Dose?
Begin with a readiness appointment rather than treating the first home dose like an ordinary injection. Ask the clinical team to confirm the dose, weekly schedule, two-injector sequence, injection technique, approved injection sites, site rotation, and instructions for a missed or interrupted dose. The patient and the caregiver who will administer treatment should both attend when possible. Written instructions and the clinic’s daytime and after-hours telephone numbers should be kept with the medication materials. The first two consecutive doses require direct healthcare-provider guidance. Afterward, the clinician must decide whether the patient or caregiver can inject correctly and recognize and manage possible hypersensitivity symptoms.
This is not a one-time administrative formality: the label calls for periodic reassessment. A caregiver who performs well during training may still need another demonstration if cognitive changes, tremor, impaired vision, anxiety, or a change in caregivers makes the process less reliable. Prepare a clean, well-lit workspace before each weekly appointment or injection. Keep the two autoinjectors together so that only one is not given by mistake, and have an approved sharps-disposal container ready. Follow the product’s current handling instructions exactly; do not improvise warming, shaking, transferring, or reusing the devices. Compared with a clinic infusion, home injection reduces travel and IV time, but it shifts more responsibility for correct dosing, observation, documentation, and emergency response to the household.
Confirming Eligibility, Amyloid Pathology, and Baseline Safety
A diagnosis of Alzheimer’s disease alone is not enough to start Leqembi. The label limits initiation to mild cognitive impairment or mild dementia, and beta-amyloid pathology must be confirmed before treatment. medicare coverage similarly requires documented beta-amyloid plaque for eligible beneficiaries. The exact confirmation method should be selected and documented by the treating team rather than assumed from memory symptoms or a family history. CMS describes the amyloid-documentation requirement for Medicare coverage. A baseline brain MRI is also required.
The clinician uses it to look for findings that may affect the risk of amyloid-related imaging abnormalities, or ARIA, including evidence of prior bleeding. Treatment should not proceed simply because the autoinjectors have arrived if the required MRI has not been obtained and reviewed. A practical pre-dose checklist should include the MRI date, the prescriber’s confirmation that it was reviewed, and the planned date of the next scan. Provide the treatment team with a complete medication and medical history, including prescription drugs, nonprescription pain relievers, aspirin, antiplatelet medicines, anticoagulants, supplements, prior strokes, seizures, head injuries, bleeding disorders, and previous reactions to injectable medicines. Prior serious hypersensitivity to lecanemab or any Leqembi excipient is a contraindication. Medication changes made by another clinician should be reported before the next dose rather than waiting for a routine Alzheimer’s follow-up.
APOE ε4, ARIA, and the Symptoms Families Must Recognize
APOE ε4 testing should be performed before treatment begins to help estimate ARIA risk. In the pivotal study, overall ARIA occurred in 45% of Leqembi-treated APOE ε4 homozygotes, compared with 19% of heterozygotes and 13% of noncarriers. Genetic status does not determine with certainty who will develop ARIA, but it materially changes the risk discussion and may influence the intensity of counseling and monitoring. ARIA is the central boxed-warning risk associated with Leqembi. It can involve brain swelling or bleeding and is often found on MRI before a person notices symptoms.
It can nevertheless become serious or fatal. Families should promptly contact the clinical team about headache, confusion, dizziness, visual changes, nausea, seizures, or focal neurologic symptoms such as new weakness, numbness, difficulty speaking, or loss of coordination. For example, if a person develops a new severe headache and trouble finding words the day after an injection, the caregiver should not assume that fatigue, dehydration, or Alzheimer’s disease explains the change. The prescriber should be contacted promptly, and emergency evaluation may be necessary. Home treatment does not authorize the household to decide independently that symptoms are harmless or to continue dosing while a possible ARIA event remains unevaluated.
Building the Weekly Injection and MRI Schedule
Put every weekly dose and required MRI on one calendar before home administration begins. The label calls for MRI monitoring at approximately one, two, three, and six months after treatment starts. For weekly subcutaneous treatment, the first follow-up scan is generally obtained before the fifth dose, and the MRI result should be reviewed before the next dose is given. The calendar should therefore distinguish between the date of the scan and the date by which the prescriber must clear continued treatment.
A workable example is to schedule injections for every Tuesday and arrange the first surveillance MRI early enough that the report can be reviewed before the next Tuesday dose. If the scan is completed but the clinic has not confirmed its review, the family should contact the treatment team instead of assuming that no news means clearance. MRI availability, transportation, insurance authorization, and report turnaround can all become practical limitations even when injections occur at home. Keep a treatment log with the date and time of each injection, confirmation that both autoinjectors were used, injection sites, immediate reactions, later symptoms, MRI dates, and calls to the clinic. The tradeoff is added recordkeeping, but a precise log can help distinguish a recurring injection-site reaction from a new neurologic problem and reduce uncertainty when several family members share caregiving duties.
Injection Reactions, Hypersensitivity, and Bleeding Risks
Local reactions can include redness, swelling, warmth, pain, itching, rash, a bump, bruising, or a collection of blood at the injection site. Headache, chills, fatigue, or fever can also occur after an injection. Record the reaction, when it began, whether it spread, and how long it lasted, then report it according to the treatment team’s instructions. Photographs may help the clinician assess a changing site reaction, but they should not delay urgent care for systemic symptoms. Serious hypersensitivity reactions—including angioedema, bronchospasm, and anaphylaxis—have occurred.
Before independent administration, the caregiver must know how to recognize facial or throat swelling, breathing difficulty, wheezing, widespread hives, collapse, or other signs of a severe reaction and how to activate emergency services. Do not give another dose after a suspected serious reaction unless the treating clinician has evaluated the event and provided instructions. Anticoagulants need special attention because Leqembi can be associated with brain bleeding. The label advises caution in people who need anticoagulant therapy or have other risk factors for intracerebral hemorrhage. In Study 2, intracerebral hemorrhage occurred in 2.5% of Leqembi recipients taking an anticoagulant alone or with aspirin or another antiplatelet drug—2 of 79 people—compared with none in the corresponding placebo group. Patients should not stop a prescribed anticoagulant on their own, but the Leqembi prescriber must know about it and about any new recommendation to start one.
Preparing the Patient, Caregiver, and Home Environment
Choose one trained primary caregiver and, if possible, a trained backup. Use the same quiet location and consistent weekly time, reduce interruptions, and check the medication and patient identity before beginning. For example, if adult siblings alternate weekend care, both should receive provider-approved training rather than relying on one sibling to explain the injection informally to the other.
Plan for observation and transportation after the dose, especially early in treatment or after a prior reaction. The person receiving Leqembi should not be left alone immediately after administration if cognitive impairment would prevent reliable reporting of headache, dizziness, visual changes, breathing problems, or swelling. Keep the prescriber’s contact information, current medication list, APOE result, MRI schedule, allergy information, and nearest emergency-department details readily accessible.
What Happens After 18 Months of Leqembi Treatment?
After 18 months, the clinician may consider a maintenance regimen. The labeled maintenance options are Leqembi 10 milligrams per kilogram intravenously every four weeks or Leqembi IQLIK 360 milligrams subcutaneously once weekly; the starting treatment regimen may also be continued. The choice is clinical rather than automatic and should account for tolerability, monitoring results, caregiver capacity, travel demands, and the patient’s current circumstances.
For a family struggling with weekly injections, a monthly IV maintenance schedule may reduce home administration duties but restore infusion-center travel and intravenous access. Another household may prefer the weekly 360-milligram subcutaneous maintenance option because it avoids clinic infusions. A change to maintenance dosing should occur only under the prescriber’s order, not by using fewer starting-dose autoinjectors or altering the weekly 500-milligram regimen at home.
Frequently Asked Questions
Can the first Leqembi IQLIK dose be given independently at home?
No. At least the first two consecutive doses must be administered under direct healthcare-provider guidance. Independent patient or caregiver administration is appropriate only after the clinician confirms that the person can inject correctly and recognize and manage hypersensitivity symptoms.
How much Leqembi IQLIK is used when starting treatment?
The at-home starting regimen is 500 milligrams subcutaneously once weekly, delivered as two 250-milligram autoinjectors.
Is an MRI still required when Leqembi is injected at home?
Yes. A baseline MRI and surveillance MRIs at approximately one, two, three, and six months are required. The first follow-up MRI is generally performed before the fifth weekly subcutaneous dose, and its result should be reviewed before the next dose.
Which symptoms could indicate ARIA?
Possible symptoms include headache, confusion, dizziness, visual changes, nausea, seizures, and focal neurologic symptoms such as weakness, numbness, speech difficulty, or impaired coordination. These symptoms warrant prompt clinical contact and evaluation.
Can someone taking an anticoagulant receive Leqembi?
Anticoagulant use does not permit a simple yes-or-no answer. The prescribing information urges caution because of intracerebral-hemorrhage risk. The Leqembi prescriber must review the specific anticoagulant, other bleeding risks, MRI findings, and clinical circumstances; patients should not stop anticoagulation without medical direction.
